Research helps us understand how to live well with diabetes and will eventually lead us to the cure.
Because of research, we have experienced monumental advancements in understanding what causes diabetes, how it affects the body, how to manage diabetes both physically and emotionally, and what contributes to the development of diabetes complications.
We encourage you to consider participation in one or more of the clinical research studies now available at UCSF and outlined below.
Type 1 Diabetes Online Clinical Trials Screener: Find out if you or a loved one may be eligible for a Type 1 Diabetes Trial.
Type 1 diabetes opportunities (Risk Screening):
TrialNet Pathway to Prevention: This study is for the relatives of people with Type 1 Diabetes. Relatives of people with T1D have up to 15 times greater risk for developing T1D. First degree relatives ages 2.5 to 45 years old and second or third degree relatives between the ages of 2.5 and 20 years old can get screened for their risk of developing T1D. The results give an early warning sign for developing diabetes and provide access to prevention trials (For example Abatacept Study, see link below) and closer monitoring. Click here to sign up online or call 844-813-8273 to schedule an appointment.
Type 1 diabetes opportunities (Prevention):
Abatacept Study: This is a prevention study for relatives of people with Type 1 Diabetes who have two or more positive auto-antibodies but don’t yet have diabetes (normal blood sugars). It is open to relatives ages 6 to 45 years old. Abatacept is an FDA approved medication for use in children as young as 6 for two types of juvenile arthritis (an autoimmune disease). Abatacept works by blocking T cells before they have a chance to attack insulin producing beta cells. (This study is currently CLOSED TO ENROLLMENT)
Hydroxychloroquine Study: This is a prevention study for relatives of people with Type 1 Diabetes who were previously enrolled in TrialNet Pathway to Prevention and were found to have two or more positive auto-antibodies. It is open to relatives ages 3 to 45 years old with normal blood sugar. Hydroxychloroquine is an FDA approved medication for treating malaria, lupus, and rheumatoid arthritis.
Type 1 diabetes opportunities (Intervention):
Tolerance Using Plasmid (TOPPLE) Study: This is a Phase I study testing the safety of a new treatment, NNC0361-0041, in adults with T1D. The treatment is a plasmid vector designed to transfer DNA into cells, where it can communicate with the immune system. It is open to adults ages 18-45 who have been diagnosed within the past 48 months.
A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (PRV-031), a Humanized. FcR Non-Binding, anti-CD3 Monoclonal Antibody, in Children and Adolescents with Newly Diagnosed Type 1 Diabetes (PROTECT study): This is an intervention study for children and adolescents ages 8 to 17 years old within 30 days of diabetes diagnosis.
A prospective, multi-center, Phase 1b/2a study to assess the safety and tolerability of different doses of AG019 administered alone or in association with teplizumab in subjects with clinical recent-onset Type 1 Diabetes Mellitus (T1D): This is an intervention study for people with Type 1 Diabetes. Participants must be 12 years old or older and have had diabetes for no more than 150 days. (This study is currently CLOSED TO ENROLLMENT)
Type 1 diabetes opportunities (Other):
PAINT1d Study: Parent-Child Art Intervention for Navigating T1D: Early childhood Type 1 onset is especially difficult to manage, both physiologically and emotionally. We want to see if we can ease some of the emotional distress and stress associated with managing diabetes in young children, especially in relation to health technology. If you can participate in 5 Art Therapy sessions with your child and in 2 separate caregiver sessions, you are likely eligible. (These sessions are conducted via Telehealth during COVID-19 restrictions.) Phone: 844-813-8273 (844-T1D-UCSF) Email: [email protected]
Perspectives on Insulin Delivery Systems by Caregivers of Children with Type 1 Diabetes (T1D): This study asks about how families living with type 1 diabetes feel about their diabetes management. It will take about 15 minutes to complete. If your child is between 13-17 years old, they'll also be asked to complete their own survey, if they would like. Children 6-17 years old with type 1 diabetes for more than 3 months using any mode of insulin delivery can participate. For more information, please email Fatema Abdulhussein, MD, at [email protected]
The Relationship between Diabetes Technology Use and Glycemic Outcomes in Pediatric Type 1 Diabetes Patients: This study looks at characteristics of the individual, family, community, and health care system and their effects on diabetes technology use, and ultimately how they relate to glycemic outcomes in adolescents with type 1 diabetes. Adolescents 12-17 years old with type 1 diabetes for more than one year, AND his/her parent or primary caregiver can participate. For more information, please email Jenny Min, MSN, RN, CPNP-PC, at [email protected]
Type 1 Diabetes Patient Preference Survey Study: This study measures patient preferences about islet cell transfusions. You will be asked to complete a series of questions online regarding your background, current treatments, and treatment preferences. The entire survey takes about 30-45 minutes to complete, and each patient who completes it will receive $20 compensation. Adults 18 years old and older with type 1 diabetes, who have experienced severe hypoglycemia can participate. For more information, please email Leslie Wilson, PhD, at [email protected] or visit http://diabetespreference.ucsf.edu/
Type 2 diabetes opportunities:
Study to Understand Gaining Access to blood glucose Records (SUGAR): In this randomized controlled trial, adults with type 2 diabetes who are 18 years of age and older will be given new blood glucose monitoring technologies to manage their diabetes.
Sensors On Youth with Type 2 Diabetes (SOY-T2): This is a pilot study of young adults with type 2 diabetes looking at how they feel about using technology to manage blood sugar levels. This study will help learn if a sensor (or continuous glucose monitoring “CGM” system) and a smartphone app are useful tools. It is open to adolescents and young adults ages 13 to 21 years old who have had type 2 diabetes for at least 6 months. If you are interested in learning more and want to be contacted, please send us a note at: [email protected] or call (415) 514-8549.
For more information:
Email: [email protected]
Call: 844-T1D-UCSF (844-813-8273)